13.33
price down icon5.46%   -0.77
pre-market  시장 영업 전:  12.80   -0.53   -3.98%
loading

Inhibrx Biosciences Inc 주식(INBX)의 최신 뉴스

pulisher
Apr 01, 2025

Inhibrx Biosciences reshuffles leadership, appoints new CSO and President By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Inhibrx Biosciences reshuffles leadership, appoints new CSO and President - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Inhibrx Biosciences Announces Departure Of CSO And Appointments Of New CSO And President - TradingView

Apr 01, 2025
pulisher
Apr 01, 2025

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President - PR Newswire

Apr 01, 2025
pulisher
Mar 26, 2025

How the (INBX) price action is used to our Advantage - Stock Traders Daily

Mar 26, 2025
pulisher
Mar 18, 2025

JMP maintains Market Perform on Inhibrx stock post-earnings - Investing.com India

Mar 18, 2025
pulisher
Mar 17, 2025

Inhibrx Biosciences, Inc. SEC 10-K Report - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Yahoo

Mar 17, 2025
pulisher
Mar 17, 2025

Inhibrx Cancer Drug Shows Complete Response as Company Posts $1.7B Annual Profit - Stock Titan

Mar 17, 2025
pulisher
Mar 15, 2025

Long Term Trading Analysis for (INBX) - Stock Traders Daily

Mar 15, 2025
pulisher
Mar 04, 2025

When (INBX) Moves Investors should Listen - Stock Traders Daily

Mar 04, 2025
pulisher
Feb 17, 2025

A closer look at Inhibrx Biosciences Inc (INBX)’s stock price trends - US Post News

Feb 17, 2025
pulisher
Feb 11, 2025

When the Price of (INBX) Talks, People Listen - Stock Traders Daily

Feb 11, 2025
pulisher
Feb 05, 2025

BlackRock, Inc. Increases Stake in Inhibrx Biosciences Inc. - GuruFocus.com

Feb 05, 2025
pulisher
Jan 31, 2025

(INBX) Trading Signals - Stock Traders Daily

Jan 31, 2025
pulisher
Jan 23, 2025

Inhibrx reports promising ozekibart trial results - MSN

Jan 23, 2025
pulisher
Jan 23, 2025

Inhibrx's SWOT analysis: oncology biotech stock faces pivotal year ahead - MSN

Jan 23, 2025
pulisher
Jan 21, 2025

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 - GuruFocus.com

Jan 21, 2025
pulisher
Jan 21, 2025

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer – Company Announcement - Financial Times

Jan 21, 2025
pulisher
Jan 21, 2025

Inhibrx's Ozekibart Shows Promising 40% Response Rate in Advanced Colorectal Cancer Trial - Stock Titan

Jan 21, 2025
pulisher
Jan 20, 2025

How to Take Advantage of moves in (INBX) - Stock Traders Daily

Jan 20, 2025
pulisher
Jan 14, 2025

Inhibrx Biosciences enters $150M loan facility - MSN

Jan 14, 2025
pulisher
Jan 14, 2025

Regeneron, Illumina invest in Truveta; Inhibrx Bio’s $150M loan - Endpoints News

Jan 14, 2025
pulisher
Jan 13, 2025

Inhibrx Biosciences, Inc. Announces Loan Agreement with Oxford Finance LLC - Marketscreener.com

Jan 13, 2025
pulisher
Jan 13, 2025

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance - StreetInsider.com

Jan 13, 2025
pulisher
Jan 13, 2025

Inhibrx Secures $150M Financing Deal to Advance Clinical Programs, Receives $100M Upfront - Stock Titan

Jan 13, 2025
pulisher
Jan 10, 2025

(INBX) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Jan 10, 2025
pulisher
Dec 30, 2024

How To Trade (INBX) - Stock Traders Daily

Dec 30, 2024
pulisher
Dec 17, 2024

Inhibrx's SWOT analysis: biotech stock faces pivotal year amid clinical trials - Investing.com India

Dec 17, 2024
pulisher
Dec 09, 2024

(INBX) Trading Report - Stock Traders Daily

Dec 09, 2024
pulisher
Dec 05, 2024

Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year By Investing.com - Investing.com Nigeria

Dec 05, 2024
pulisher
Dec 05, 2024

Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year - Investing.com

Dec 05, 2024
pulisher
Dec 02, 2024

2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy - News & Insights

Dec 02, 2024
pulisher
Nov 22, 2024

Inhibrx Biosciences director Jon Faiz Kayyem buys $1.52m in stock - Investing.com Nigeria

Nov 22, 2024
pulisher
Nov 18, 2024

Trend Tracker for (INBX) - Stock Traders Daily

Nov 18, 2024
pulisher
Nov 17, 2024

The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares - Yahoo Finance

Nov 17, 2024
pulisher
Nov 17, 2024

institutional investors of Inhibrx Biosciences, Inc. (NASDAQ:INBX) must be disappointed after last week's 15% drop - Simply Wall St

Nov 17, 2024
pulisher
Nov 15, 2024

Perceptive Advisors LLC Bolsters Stake in Inhibrx Biosciences Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Inhibrx Biosciences Inc (INBX) Quarterly 10-Q Report - Quartzy

Nov 15, 2024
pulisher
Nov 14, 2024

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PR Newswire

Nov 14, 2024
pulisher
Nov 12, 2024

Inhibrx Biosciences Inc. (INBX) Quarterly 10-Q Report - Quartzy

Nov 12, 2024
pulisher
Nov 09, 2024

Wilson Sonsini Knocks Out Claims Against Inhibrx Biosciences in Trade Secrets Verdict - Law.com

Nov 09, 2024
pulisher
Nov 07, 2024

Inhibrx Biosciences’ Trade Secret Case - Global Legal Chronicle

Nov 07, 2024
pulisher
Nov 05, 2024

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha

Nov 05, 2024
pulisher
Nov 04, 2024

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation - Financial Times

Nov 04, 2024
pulisher
Oct 25, 2024

James Sabry on industry-shaping changes in innovation and deal-making - BioCentury

Oct 25, 2024
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
자본화:     |  볼륨(24시간):